Chardan analyst Keay Nakae lowered the firm’s price target on Omega Therapeutics to $6 from $7 and keeps a Buy rating on the shares post the Q2 report. The lower price target reflects a higher projected future share count as modeled future capital raises are expected to be more dilutive due to the decline in share price over the last quarter, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMGA:
- Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
- Omega Therapeutics announces election of Richard Kender to its board
- Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors
- Omega Therapeutics initiated with an Outperform at Raymond James